Businesses for Sale

This opportunity is not suitable for an individual or independent sponsor without committed funds.

This company is an established ambulatory infusion provider with a long operating history and a multi-site network of outpatient infusion centers. Supported by an in-house licensed pharmacy and a centralized billing and reimbursement team, it administers more than 20,000 patient infusions a year – predominantly long-term biologic therapies for chronic and rare diseases – in a lower-cost, close-to-home alternative to hospital outpatient infusion.

INVESTMENT HIGHLIGHTS:

✔    Recurring, Life-Sustaining Revenue:  94.6% of drug revenue comes from long-term maintenance therapies, including more than $18 million a year from life-sustaining treatments patients cannot stop.
✔    Scale and Growth:  Revenue grew 25% from $68.2 million in 2023 to $85.6 million for the twelve months ended June 2026, with first-half 2026 revenue up 13% year over year.
✔    Highly Diversified Referral Base:  More than 800 ordering providers; the top 10 referral sources represent 19% of revenue and no single source exceeds 3.3%.
✔    Demand Exceeds Capacity:  Its highest-volume centers operate at full capacity, with patient encounters up 11% and revenue per encounter up 13% since 2023 on roughly 3,400 new patient orders a year.
✔    Integrated Platform:  In-house licensed pharmacy, centralized billing (32-day DSO, ~90% appeal success) and more than 50 therapies, with no single drug above 15% of revenue.
✔    Experienced Team in Place:  Clinical leadership and a tenured management team are expected to remain in place after the transaction, supporting a seamless transition.

GROWTH OPPORTUNITIES:

• Capacity Expansion:  Several centers operate part-week schedules and can add operating days without new space, and chairs can be added where demand is highest.
• Specialty Pharmacy:  Recently credentialed with the major PBMs, opening a new revenue stream for therapies payors route outside buy-and-bill.
• Platform and Purchasing Scale:  An acquirer can apply its purchasing leverage to roughly $76 million of annual drug spend and absorb about $1.6 million of corporate overhead.
• Site-of-Care Shift and New Markets:  Payor and CMS policies continue to move infusions out of hospitals; growth to date has come almost entirely from word of mouth.

• BID Asking Price
• $3M Cash Flow
• $86.5M Gross Revenue